| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
| Targets |
Palmitoylglycine targets calcium channels and nitric oxide synthase in sensory neurons. It modulates calcium influx and stimulates NO production. The compound inhibits heat-evoked firing of wide dynamic range (WDR) neurons. It is also explored for its potential in modulating vesicle behavior and influencing lipid packing.
|
|---|---|
| ln Vitro |
In vitro, Palmitoylglycine has been shown to activate calcium influx in dorsal root ganglion (DRG) cells and stimulate NO production. The compound modulates calcium influx and NO production in sensory neurons. It inhibits heat-evoked firing of wide dynamic range neurons, indicating a role in pain modulation.
|
| ln Vivo |
In vivo, Palmitoylglycine has been studied for its effects on pain modulation. The compound is an endogenous signaling lipid that may play a role in nociception. Detailed in vivo data regarding dosage, administration routes, and specific efficacy endpoints are limited in the available literature.
|
| Enzyme Assay |
Palmitoylglycine's receptor-binding activity has been studied in neuronal cell systems. The compound was shown to modulate calcium influx and NO production in sensory neurons. Detailed enzyme inhibition assays or receptor binding studies with purified proteins are not extensively reported in the available literature.
|
| Cell Assay |
In vitro cell experiments with Palmitoylglycine typically use DRG sensory neurons. Cells are treated with the compound at various concentrations, and calcium influx is measured using fluorescent calcium indicators. NO production is assessed using Griess assay or fluorescent probes. The compound's effects on heat-evoked firing are measured using electrophysiological recordings.
|
| Animal Protocol |
In vivo animal studies with Palmitoylglycine have been conducted using rodent models of pain. The compound is typically administered via intrathecal or systemic routes. Detailed protocols regarding dosage, treatment duration, and specific animal models are not extensively reported in the available literature.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data specific to Palmitoylglycine are limited in the available literature. As an endogenous lipid, the compound is expected to be rapidly metabolized and cleared. Further pharmacokinetic studies are needed to fully characterize its absorption, distribution, metabolism, and excretion properties.
|
| Toxicity/Toxicokinetics |
Toxicological data for Palmitoylglycine are limited. As an endogenous lipid, the compound is naturally present in the body and is generally considered to have a favorable safety profile. However, comprehensive toxicological studies have not been extensively reported. As a research compound, it is intended for laboratory use only and not for human consumption.
|
| References | |
| Additional Infomation |
N-Hexadecanoylglycine is an N-acylglycine, where the acyl group is specifically defined as hexadecanoyl (palmitoyl). It is a metabolite found in both marine and human organisms. It is a fatty amide, belonging to the N-acylglycine 16:0 group. Its function is related to hexadecanoic acid. It is the conjugate acid of N-hexadecanoylglycine. N-palmitoylglycine has been reported to exist in Euglena gracilis, and relevant data are available for reference.
Palmitoylglycine (N-palmitoyl glycine) is an endogenous signaling lipid with a molecular weight of 313.48 and a purity of 99.84%. The compound has been studied for its potential role in pain modulation and neuronal signaling. It is also explored for its potential in modulating vesicle behavior and contributing to research on acyl-amino lipid signaling mechanisms. |
| Molecular Formula |
C18H35NO3
|
|---|---|
| Molecular Weight |
313.4754
|
| Exact Mass |
313.261
|
| CAS # |
2441-41-0
|
| Related CAS # |
Palmitoylglycine-d31
|
| PubChem CID |
151008
|
| Appearance |
White to off-white solid powder
|
| Density |
1.0±0.1 g/cm3
|
| Boiling Point |
491.8±28.0 °C at 760 mmHg
|
| Flash Point |
251.2±24.0 °C
|
| Vapour Pressure |
0.0±2.7 mmHg at 25°C
|
| Index of Refraction |
1.468
|
| LogP |
6.03
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
16
|
| Heavy Atom Count |
22
|
| Complexity |
280
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
KVTFEOAKFFQCCX-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C18H35NO3/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-17(20)19-16-18(21)22/h2-16H2,1H3,(H,19,20)(H,21,22)
|
| Chemical Name |
2-(hexadecanoylamino)acetic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~5 mg/mL (~15.95 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.1900 mL | 15.9500 mL | 31.9000 mL | |
| 5 mM | 0.6380 mL | 3.1900 mL | 6.3800 mL | |
| 10 mM | 0.3190 mL | 1.5950 mL | 3.1900 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
